Abstract Alzheimer's disease (AD), as the fourth leading cause of death among the elderly
worldwide, has brought enormous challenge to the society. Due to its extremely complex …

Alzheimer's disease is a most prevalent form of dementia all around the globe and currently
poses a significant challenge to the healthcare system. Currently available drugs only slow …

Alzheimer's disease (AD) is a chronic neurodegenerative disease that 4 widespread in the
elderly. The etiology of AD is complicated, and its pathogenesis is still unclear. Although …

Highlights•BChE is considered a promising drug target for the treatment of moderate to
severe Alzheimer's disease.•The development of selective BChE inhibitors will move on …

Niemann− Pick type C (NPC) disease is a lysosomal storage disorder characterized at the
cellular level by abnormal accumulation of cholesterol and other lipids in lysosomal storage …

A series of novel chalcone-rivastigmine hybrids were designed, synthesized, and tested in
vitro for their ability to inhibit human acetylcholinesterase and butyrylcholinesterase. Most of …

Abstract Acetylcholinesterase (AChE) and butyrylcholinesterase (BChE) are enzymes that
serve a wide range of physiological functions including the hydrolysis of the neurotransmitter …

Isosorbide-2-benzyl carbamate-5-benzoate is a highly potent and selective BuChE inhibitor.
Meanwhile, isosorbide-2-aspirinate-5-salicylate is a highly effective aspirin prodrug that …

Butyrylcholinesterase (BChE) is recently considered as a new target for the treatment of
Alzheimer's disease (AD). There is an increasing interest in the development of BChE …

A striking dual inhibition of enzymes α-glucosidase and butyrylcholinesterase by small drug-
like molecules, including 1, 4-disubstituted-1, 2, 3-triazoles, chalcones, and …